Lobbying client

PRIMMUNE THERAPEUTICS

Biotechnology Company

Filings
12
Filed by
1
Reported in-house
—
Reported by firms
$120,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2020 to 2022

Filings

12 filings, newest first.
Filing Filed by Amount
3rd Quarter - Termination
3rd Quarter 2022
FORBES-TATE — reported
2nd Quarter - Report
2nd Quarter 2022
FORBES-TATE — reported
1st Quarter - Report
1st Quarter 2022
FORBES-TATE — reported
4th Quarter - Report
4th Quarter 2021
FORBES-TATE — reported
3rd Quarter - Report
3rd Quarter 2021
FORBES-TATE — reported
2nd Quarter - Report
2nd Quarter 2021
FORBES-TATE — reported
1st Quarter - Report
1st Quarter 2021
FORBES-TATE — reported
4th Quarter - Report
4th Quarter 2020
FORBES-TATE $40,000 reported
3rd Quarter - Report
3rd Quarter 2020
FORBES-TATE $20,000 reported
2nd Quarter - Report
2nd Quarter 2020
FORBES-TATE $30,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
FORBES-TATE 11 $120,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 12
Budget/Appropriations BUD 2

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
H.R. 925 116th 2

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.